Lysosome-targeting agents in cancer therapy

Guido Kroemer; Lorenzo Galluzzi

doi:10.18632/oncotarget.21451

Lysosome-targeting agents in cancer therapy

Guido Kroemer, Lorenzo Galluzzi

Research output: Contribution to journal › Article › peer-review

13 Citations (Scopus)

Abstract

Despite considerable efforts from multiple laboratories worldwide, highly specific inhibitors of autophagy for clinical use are not yet available. Lysosomal inhibitors are being employed instead, in spite of multiple limitations that are summarized herein.

Original language	English
Pages (from-to)	112168-112169
Number of pages	2
Journal	Oncotarget
Volume	8
Issue number	68
DOIs	https://doi.org/10.18632/oncotarget.21451
Publication status	Published - 1 Jan 2017

Keywords

Anticancer immunosurveillance
Autophagy
Chemotherapy
Chloroquine
Hydroxychloroquine

Access to Document

10.18632/oncotarget.21451

Cite this

@article{ca26f2e1424c4dc58baad0011d78ae0e,

title = "Lysosome-targeting agents in cancer therapy",

abstract = "Despite considerable efforts from multiple laboratories worldwide, highly specific inhibitors of autophagy for clinical use are not yet available. Lysosomal inhibitors are being employed instead, in spite of multiple limitations that are summarized herein.",

keywords = "Anticancer immunosurveillance, Autophagy, Chemotherapy, Chloroquine, Hydroxychloroquine",

author = "Guido Kroemer and Lorenzo Galluzzi",

note = "Publisher Copyright: {\textcopyright} Kroemer et al.",

year = "2017",

month = jan,

day = "1",

doi = "10.18632/oncotarget.21451",

language = "English",

volume = "8",

pages = "112168--112169",

journal = "Oncotarget",

issn = "1949-2553",

number = "68",

}

TY - JOUR

T1 - Lysosome-targeting agents in cancer therapy

AU - Kroemer, Guido

AU - Galluzzi, Lorenzo

N1 - Publisher Copyright: © Kroemer et al.

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Despite considerable efforts from multiple laboratories worldwide, highly specific inhibitors of autophagy for clinical use are not yet available. Lysosomal inhibitors are being employed instead, in spite of multiple limitations that are summarized herein.

AB - Despite considerable efforts from multiple laboratories worldwide, highly specific inhibitors of autophagy for clinical use are not yet available. Lysosomal inhibitors are being employed instead, in spite of multiple limitations that are summarized herein.

KW - Anticancer immunosurveillance

KW - Autophagy

KW - Chemotherapy

KW - Chloroquine

KW - Hydroxychloroquine

UR - http://www.scopus.com/inward/record.url?scp=85038834025&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.21451

DO - 10.18632/oncotarget.21451

M3 - Article

C2 - 29348815

AN - SCOPUS:85038834025

SN - 1949-2553

VL - 8

SP - 112168

EP - 112169

JO - Oncotarget

JF - Oncotarget

IS - 68

ER -

Lysosome-targeting agents in cancer therapy

Abstract

Keywords

Access to Document

Other files and links

Cite this